@article{ATM18087,
author = {Jacques Cadranel},
title = {Osimertinib in first-line treatment—is a comparison not proof?},
journal = {Annals of Translational Medicine},
volume = {6},
number = {3},
year = {2018},
keywords = {},
abstract = {Considerable progress has been made in the treatment of advanced non-small-cell lung carcinoma (NSCLC) harboring an epidermal growth factor receptor (EGFR) gene mutation (EGFR-NSCLC) since the publication of the BR21 trial (1). That trial showed erlotinib to have a modest effect compared with placebo in the second and subsequent lines of treatment in the all-comers NSCLC population.},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/18087}
}